The Testing Evidence for Using Ivermectin for Treating Gastric Cancer or Digestive Cancer
Executive Summary
- Ivermectin is proven to treat a variety of different cancers.
- Gastric cancer or digestive cancer is one of them.
Executive Summary
- This article covers the evidence I could find for Ivermectin as a treatment for gastric cancer or digestive cancer.
Introduction
Many articles on this website cover the evidence for the benefits of Ivermectin for cancer. But the question of which specific cancers Ivermectin has been proven effective is a constant source of questions.
This article provides an overview covering the evidence for Ivermectin versus gastric cancer or digestive cancer.
The article uses the term “IVM” to mean Ivermectin.
There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin.
Cancer Type #2: Gastric Cancer or Digestive Cancer
Here is the study finding from Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer.
Ivermectin Reduces Tumor Size Which Was Associated With Inactivation of WNT/β-Catenin Signaling, Down Regulation of Cell Proliferation and Upregulation of Cell Death Signaling Networks
Ivermectin Inhibits Cell Proliferation and Induces Cell Cycle Arrest.
Nambara’s study showed that IVM could significantly inhibit the proliferation of gastric cancer cells in vivo and in vitro and that the inhibitory effect of IVM depended on the expression of Yes-associated protein 1(YAP1) – NIH
This study was funded by science foundations and hospitals out of Norway.
The Importance of The NIH Stopping Any Funding For Ivermectin Studies
Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.
Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.
Testing Evidence for Ivermectin
The following quotes are from the article Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Impact #1: Inhibiting Proliferation of Tumor Cells
Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways.
The Ivermectin blocking of PAK1 proteins, aka activated kinase, is a reason for this.
The instrumentality of PAK1 in cancer growth is explained in the following quotation from the article Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations.
In human gastric cancer or digestive cancer and NF2 tumor cell lines, high-dose ivermectin inactivates protein kinase PAK1 and blocks PAK1-dependent growth.
PAK proteins are essential for cytoskeletal reorganization and nuclear signaling, PAK1 being implicated in tumor genesis while inhibiting PAK1 signals induces tumor cell apoptosis (cell death).
PAK1 is essential for the growth of more than 70% of all human cancers, including breast, prostate, pancreatic, colon, gastric, lung, cervical and thyroid cancers, as well as hepatoma, glioma, melanoma, multiple myeloma and for neurofibromatosis tumors.
PAK1 becomes hyperactive in cancer cells for reasons that are not yet understood.
Ivermectin can be viewed as a PAK1 restrictor or modulator (I say modulator as PAK1 is present in normal healthy cells, but an overage of PAK is a prime cause of cancer. This means that Ivermectin interferes with a precursor to cancer. This modulating influence on PAK is another reason Ivermectin is effective against many types of cancer.
PAK1 is implicated in multiple cancers if found in the quotation from the article Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.
The Importance of The NIH Stopping Any Funding For Ivermectin Studies
Notice that none of the studies on Ivermectin were performed in the US. The US has by far the largest national medical research budget in the world, and so if the US is not performing studies, this is not only a negative but tells us something peculiar about what the NIH is deciding not to fund in the area of cancer research.
Zero is the number of studies funded by the NIH on Ivermectin. The NIH will not fund studies into generic drugs, as the NIH is controlled by pharmaceutical companies and they have deep financial ties to them. Funding research into generic drugs could end up showing those drugs as effective, which is a threat to pharmaceutical profits, which the NIH is dedicated to maximizing.
Interested in More?
Would you like to get access to 100% independent medical information?
Regarding the dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.
